Jan Orwar
Direktor/Vorstandsmitglied bei FLUICELL AB
Aktive Positionen von Jan Orwar
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
FLUICELL AB | Direktor/Vorstandsmitglied | 01.01.2015 | - |
Chalmers University of Technology | Corporate Officer/Principal | 17.01.2011 | - |
Direktor/Vorstandsmitglied | - | 17.01.2011 | |
Karolinska Institutet | Corporate Officer/Principal | - | - |
Karriereverlauf von Jan Orwar
Ehemalige bekannte Positionen von Jan Orwar
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Nanoxis AB
Nanoxis AB Miscellaneous Commercial ServicesCommercial Services Nanoxis AB provides tools and services for membrane protein research. It specializes in research and development of nanofabrication technologies in soft polymer and fluid-state liquid crystalline material. The company was founded by Owe Orwar and Anders Karlsson in November 2002 and is headquartered in Gothenburg, Sweden. | Direktor/Vorstandsmitglied | 01.11.2002 | 11.02.2014 |
Gründer | 29.10.2009 | 11.02.2014 | |
Corporate Officer/Principal | 29.10.2009 | 11.02.2014 | |
PIRAMAL ENTERPRISES LIMITED | Technik-/Wissenschafts-/F&E-Leiter | - | - |
Sanofi AB
Sanofi AB Medical DistributorsDistribution Services Part of Sanofi, Sanofi AB is a pharmaceutical company based in Stockholm, Sweden. The Swedish company's description states that it is an international pharmaceutical company. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
Oblique Therapeutics AB
Oblique Therapeutics AB Pharmaceuticals: MajorHealth Technology Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022. | Vorstandsvorsitzender | - | - |
Technik-/Wissenschafts-/F&E-Leiter | - | - | |
Gründer | - | - | |
Cellectricon AB
Cellectricon AB Miscellaneous Commercial ServicesCommercial Services Cellectricon AB provides cell-based screening services to accelerate drug discovery. The firm develops and validates exciting central nervous system and peripheral pain assays using primary cells, accelerating the path from assay validation to compound screening. Its system is equipped with an imaging-based microplate reader to simultaneously record transient fluorescence and luminescence signals, providing real-time monitoring and readouts of cell culture response. The company was founded by Jan Owe Owesson Orwar, Daniel T. Chiu and Stig Anders Jakob Lindberg in 1999 and is headquartered in Molndal, Sweden. | Direktor/Vorstandsmitglied | 01.01.2000 | - |
Technik-/Wissenschafts-/F&E-Leiter | 01.01.2000 | 29.10.2009 | |
Gründer | 29.10.2009 | - |
Ausbildung von Jan Orwar
University of Gothenburg | Doctorate Degree |
Stanford University | Doctorate Degree |
Statistik
International
Schweden | 9 |
Vereinigte Staaten | 2 |
Indien | 2 |
Operativ
Director/Board Member | 4 |
Chief Tech/Sci/R&D Officer | 4 |
Founder | 3 |
Sektoral
Consumer Services | 5 |
Commercial Services | 3 |
Health Technology | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
PIRAMAL ENTERPRISES LIMITED | Finance |
FLUICELL AB | Health Technology |
Private Unternehmen | 4 |
---|---|
Cellectricon AB
Cellectricon AB Miscellaneous Commercial ServicesCommercial Services Cellectricon AB provides cell-based screening services to accelerate drug discovery. The firm develops and validates exciting central nervous system and peripheral pain assays using primary cells, accelerating the path from assay validation to compound screening. Its system is equipped with an imaging-based microplate reader to simultaneously record transient fluorescence and luminescence signals, providing real-time monitoring and readouts of cell culture response. The company was founded by Jan Owe Owesson Orwar, Daniel T. Chiu and Stig Anders Jakob Lindberg in 1999 and is headquartered in Molndal, Sweden. | Commercial Services |
Nanoxis AB
Nanoxis AB Miscellaneous Commercial ServicesCommercial Services Nanoxis AB provides tools and services for membrane protein research. It specializes in research and development of nanofabrication technologies in soft polymer and fluid-state liquid crystalline material. The company was founded by Owe Orwar and Anders Karlsson in November 2002 and is headquartered in Gothenburg, Sweden. | Commercial Services |
Oblique Therapeutics AB
Oblique Therapeutics AB Pharmaceuticals: MajorHealth Technology Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022. | Health Technology |
Sanofi AB
Sanofi AB Medical DistributorsDistribution Services Part of Sanofi, Sanofi AB is a pharmaceutical company based in Stockholm, Sweden. The Swedish company's description states that it is an international pharmaceutical company. | Distribution Services |